Skip to main content
GutCited

Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans.

I Sakamoto, M Igarashi, K Kimura, A Takagi, T Miwa et al.
Other The Journal of antimicrobial chemotherapy 2001 309 Zitierungen
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'pmid\u003D11328791'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Studientyp
Controlled Clinical Trial
Stichprobengröße
31
Population
H. pylori-infected subjects
Dauer
8 weeks
Intervention
Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans. LG21 yogurt daily for 8 weeks
Vergleichsgruppe
Before-after comparison
Primärer Endpunkt
H. pylori suppression (UBT, pepsinogens)
Wirkungsrichtung
Positive
Verzerrungsrisiko
Moderate

Abstract

To examine the efficacy of Lactobacillus gasseri OLL2716 (LG21) as a probiotic for Helicobacter pylori in humans, 31 subjects infected with the bacterium ingested yogurt containing LG21 daily for an 8 week period. The [(13)C]urea breath test and assays of serum pepsinogens revealed a significant improvement following LG21 treatment. LG21 was thus determined to be effective in both suppressing H. pylori and reducing gastric mucosal inflammation.

Zusammenfassung

LG21 was determined to be effective in both suppressing H. pylori and reducing gastric mucosal inflammation and a significant improvement following LG21 treatment.

Used In Evidence Reviews

Similar Papers